Company Study of Shanghai Kehua Bio-engineering 
  • Jul/2007
  • Hard Copy
  • USD $299
  • Pages:18
  • Single User License
    (PDF Unprintable)       
  • USD $299
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $598
  • Hard Copy + Single User License
  • USD $349
      

After decades' development, the number of enterprises in China diagnostic reagents industry decreased from more than 300 to 80 or so at present. Several large-size enterprises take the majority of market shares. The targeted markets are mainly focused on major diseases such as hepatitis B, hepatitis C, AIDS and syphilitic disease, etc.

Shanghai Kehua Bio-engineering Co., Ltd. started to enter the field of nucleic acid diagnostic reagents in 2003. With the completion of nucleic acid PCR R&D and Production Platform, the Company now has three product categories for hepatitis B, hepatitis C and HIV/AIDS nucleic diagnosis.

The sales revenue of nucleic acid diagnostic reagents only reached RMB 3 million in 2005, while the figure in 2006 rocketed to more than RMB 8 million with a year-on-year growth of 148%.

In 2006, the sales revenue of medical instruments developed by the Company amounted to RMB 17.21 million, up 46.89% from a year earlier. The average growth in recent three years reached as high as about 55%.

Composition of China Diagnostic Reagents Industry



Main Business Revenue Composition of Kehua Bio-Engineering, 2006




1 Business Status Quo and Future Development Strategy
1.1 Diagnostic Reagents
1.2 Future Development

2 Extension of Production Lines
2.1 R&D Investment
2.2 Development of Nucleic Acid Diagnosis
2.3 Business of Medical Instruments

3 Analysis of Corporate Marketing Strategy
3.1 Domestic Market
3.2 Overseas Market
Composition of China Diagnostic Reagents Industry
Main Business Revenue Composition of Kehua Bio-engineering, 2006
Concentration of Main Product Markets in China
Options for Future Development of Kehua Bio-engineering
Staff Composition of Kehua Bio-engineering
Statistics on Product Reserve of Kehua Bio-engineering
Layout of Sales Agencies of Kehua Bio-engineering
Reported Number of Infectious Diseases in China
Sales Patterns of Kehua Bio-engineering
Distribution of AIDS Infected Groups Worldwide, 2006
Analysis of Corporate Advantages
Status Quo of Overseas Development

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号